Los puntos clave no están disponibles para este artículo en este momento.
The consistent improvements in GETE, lung function, and PROs, and reductions in asthma exacerbations, OCS use, and HCRU with add-on omalizumab in real-life confirm and complement the efficacy data of RCTs.
Bousquet et al. (Thu,) studied this question.